Scandion Oncology A/S

As of December 31, 2024, Scandion Oncology A/S has 234.76M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Scandion Oncology A/S maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.80, indicating moderate leverage, while an interest coverage ratio of -74.54 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -138.75, reflecting losses generated across the asset base.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -269.26: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -131.76, meaning Scandion Oncology A/S raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Scandion Oncology A/S's most recent stock split took place on May 31, 2024 with a 250:447 split ratio.

As of December 31, 2024, Scandion Oncology A/S has an Altman Z-Score of -24.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.